Your session is about to expire
What is Actoplus Met Xr
MetforminThe Generic name of this drug
Treatment SummaryPioglitazone is a medication used to treat type 2 diabetes. It is often taken in combination with diet, exercise, and other diabetes medications. This drug works by increasing the body's sensitivity to insulin and helping to lower blood sugar levels. It is part of a class of drugs called thiazolidinediones, which also includes rosiglitazone and troglitazone. Although pioglitazone can be effective, it has been linked to side effects such as congestive heart failure and bladder cancer, so it is not as widely used as other treatments for type 2 diabetes.
Metformin Hydrochlorideis the brand name
Actoplus Met Xr Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Metformin Hydrochloride
Metformin
2002
1263
Approved as Treatment by the FDA
Metformin, otherwise known as Metformin Hydrochloride, is approved by the FDA for 16 uses which include Congestive Heart Failure and Physical Activity .Congestive Heart Failure
Used to treat Heart Failure in combination with Dapagliflozin
Physical Activity
Used to treat Exercise in combination with Dapagliflozin
Type 2 Diabetes
Used to treat Type 2 Diabetes Mellitus in combination with Dapagliflozin
Hospitalizations
Used to treat Hospitalizations in combination with Dapagliflozin
Diet
Used to treat Diet in combination with Dapagliflozin
Type 1 Diabetes
Used to treat Type 1 Diabetes Mellitus in combination with Sitagliptin
Chronic Kidney Disease
Used to treat Chronic Kidney Disease (CKD) in combination with Dapagliflozin
NYHA Functional Class II-IV Heart Failure
Used to treat NYHA Functional Class II-IV Heart Failure in combination with Dapagliflozin
Ejection fraction decreased
Used to treat Ejection fraction decreased in combination with Dapagliflozin
Diabetic Ketoacidosis
Used to treat Diabetic Ketoacidosis in combination with Saxagliptin
uncontrolled diabetes
Used to treat uncontrolled diabetes in combination with Rosiglitazone
Cardiovascular Disease
Used to treat Cardiovascular Risk in combination with Dapagliflozin
Cardiovascular Diseases
Used to treat established cardiovascular disease in combination with Dapagliflozin
decreased estimated glomerular filtration rate
Used to treat decreased estimated glomerular filtration rate in combination with Dapagliflozin
Cardiovascular Mortality
Used to treat Cardiovascular Mortality in combination with Dapagliflozin
Kidney Failure
Used to treat End Stage Renal Disease (ESRD) in combination with Dapagliflozin
Effectiveness
How Actoplus Met Xr Affects PatientsPioglitazone helps your body respond better to insulin, allowing it to better manage glucose. This can help lower your blood glucose, insulin, and HbA1c levels. However, taking this medication can cause fluid retention and make existing heart failure worse, so it should not be used in those with heart failure or those at risk of developing heart failure. Additionally, there is evidence that pioglitazone may increase the risk of bladder cancer, so it should not be used in those with active bladder cancer and should be used with caution in those with a history of bladder cancer.
How Actoplus Met Xr works in the bodyPioglitazone helps make the body more sensitive to insulin, which helps lower blood sugar levels. It does this by activating PPAR-gamma, a protein in the body that helps control glucose and lipid production. This increases the body's response to insulin and decreases the amount of glucose produced by the liver. This helps with insulin resistance, a condition associated with type 2 diabetes.
When to interrupt dosage
The recommended measure of Actoplus Met Xr is contingent upon the identified condition, such as Diet, Physical Activity and Type 2 Diabetes. The quantity of dosage is contingent upon the mode of delivery (e.g. Tablet, film coated or Tablet, film coated - Oral) featured in the table underneath.Condition
Dosage
Administration
decreased estimated glomerular filtration rate
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Diabetic Ketoacidosis
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Type 1 Diabetes
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Polycystic Ovarian Syndrome
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Congestive Heart Failure
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Physical Activity
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Type 2 Diabetes
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Chronic Kidney Disease
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Kidney Failure
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Diet
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Hospitalizations
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Cardiovascular Disease
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Cardiovascular Mortality
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
inadequate response to metformin
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Ejection fraction decreased
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
NYHA Functional Class II-IV Heart Failure
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Cardiovascular Diseases
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
uncontrolled diabetes
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
diet and exercise not sufficient for diabetes control
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Warnings
Actoplus Met Xr ContraindicationsCondition
Risk Level
Notes
severe hepatic dysfunction
Do Not Combine
Impaired Renal Function
Do Not Combine
cardiovascular collapse
Do Not Combine
Diabetic Ketoacidosis
Do Not Combine
Operative Surgery
Do Not Combine
Metabolic acidosis
Do Not Combine
cardiorespiratory insufficiency caused by Heart Failure
Do Not Combine
Impaired Renal Function
Do Not Combine
kidney function unknown
Do Not Combine
Hypovolemic Shock
Do Not Combine
serum creatinine above upper limit for age range
Do Not Combine
ethanol
Do Not Combine
Acute Coryza
Do Not Combine
Hypoxemia
Do Not Combine
Liver Failure
Do Not Combine
Lactic Acidosis
Do Not Combine
Diabetic Ketoacidosis
Do Not Combine
Impaired Renal Function
Do Not Combine
estimated GFR <30mL/min
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Metformin may interact with Pulse Frequency
Common Actoplus Met Xr Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The excretion of Abemaciclib can be decreased when combined with Metformin.
Procainamide
Major
The excretion of Procainamide can be decreased when combined with Metformin.
Topotecan
Major
The excretion of Topotecan can be decreased when combined with Metformin.
Abacavir
Minor
Metformin may decrease the excretion rate of Abacavir which could result in a higher serum level.
Aclidinium
Minor
Metformin may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Actoplus Met Xr Toxicity & Overdose RiskIn mice, the lowest toxic dose of pioglitazone is 24mg/kg over a period of 4 days and in rats 3mg/kg over 6 days. In one instance of overdose, a patient ingested 120mg for 4 days and 180mg for 7 days without any reported adverse symptoms. In case of overdose, medical professionals should provide supportive care according to the patient's condition.
Actoplus Met Xr Novel Uses: Which Conditions Have a Clinical Trial Featuring Actoplus Met Xr?
300 active clinical trials are being conducted to assess the utility of Actoplus Met XR in managing Type 2 Diabetes, Type 2 Diabetes Mellitus and Physical Activity.Condition
Clinical Trials
Trial Phases
inadequate response to metformin
0 Actively Recruiting
Type 1 Diabetes
143 Actively Recruiting
Phase 3, Phase 1, Early Phase 1, Not Applicable, Phase 2, Phase 4
Cardiovascular Disease
30 Actively Recruiting
Not Applicable, Phase 1, Early Phase 1, Phase 3, Phase 2
Type 2 Diabetes
192 Actively Recruiting
Phase 2, Not Applicable, Early Phase 1, Phase 1, Phase 4, Phase 3
Chronic Kidney Disease
115 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 4, Phase 3, Early Phase 1
Polycystic Ovarian Syndrome
9 Actively Recruiting
Phase 1, Not Applicable, Phase 2, Phase 3, Early Phase 1, Phase 4
Diabetic Ketoacidosis
3 Actively Recruiting
Phase 2, Early Phase 1, Not Applicable
decreased estimated glomerular filtration rate
0 Actively Recruiting
Kidney Failure
54 Actively Recruiting
Phase 3, Phase 1, Phase 2, Phase 4, Not Applicable
Congestive Heart Failure
312 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1, Phase 4
Diet
5 Actively Recruiting
Not Applicable
uncontrolled diabetes
0 Actively Recruiting
NYHA Functional Class II-IV Heart Failure
0 Actively Recruiting
Ejection fraction decreased
0 Actively Recruiting
Hospitalizations
2 Actively Recruiting
Not Applicable
Cardiovascular Diseases
0 Actively Recruiting
Physical Activity
39 Actively Recruiting
Not Applicable, Phase 2, Phase 1, Early Phase 1
Cardiovascular Mortality
0 Actively Recruiting
diet and exercise not sufficient for diabetes control
0 Actively Recruiting
Actoplus Met Xr Reviews: What are patients saying about Actoplus Met Xr?
4.7Patient Review
10/20/20104Patient Review
3/8/2012 The price is unfortunately quite high.
Patient Q&A Section about actoplus met xr
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What type of drug is Actoplus Met?
"Actoplus MET is a prescription drug used to treat the symptoms of type 2 diabetes mellitus. It may be used alone or with other medications. It belongs to a class of drugs called antidiabetics and biguanides/thiazolidinediones. It is not known if it is safe and effective in children."
Answered by AI
What is the generic name for Actoplus Met?
"The drug Actos is available in both brand-name and generic form, with the latter being called pioglitazone. A generic drug is an exact replica of the active ingredient in a brand-name medication."
Answered by AI
What is Actoplus Met used for?
"Actoplus Met is a combination of two oral diabetes medicines, metformin and pioglitazone, that help control blood sugar levels. It is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus who do not use daily insulin injections."
Answered by AI
Is Actoplus Met XR discontinued?
"The ActoPlus Met XR brand will no longer be available in the United States. If the Food and Drug Administration has approved generic versions of this product, there may be generic equivalents available."
Answered by AI